JPWO2020209285A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020209285A5 JPWO2020209285A5 JP2021513667A JP2021513667A JPWO2020209285A5 JP WO2020209285 A5 JPWO2020209285 A5 JP WO2020209285A5 JP 2021513667 A JP2021513667 A JP 2021513667A JP 2021513667 A JP2021513667 A JP 2021513667A JP WO2020209285 A5 JPWO2020209285 A5 JP WO2020209285A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- acid strand
- composition according
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025081949A JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019073832 | 2019-04-08 | ||
| JP2019073832 | 2019-04-08 | ||
| PCT/JP2020/015818 WO2020209285A1 (ja) | 2019-04-08 | 2020-04-08 | 筋疾患治療用医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081949A Division JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020209285A1 JPWO2020209285A1 (https=) | 2020-10-15 |
| JPWO2020209285A5 true JPWO2020209285A5 (https=) | 2023-04-17 |
| JP7687682B2 JP7687682B2 (ja) | 2025-06-03 |
Family
ID=72750688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513667A Active JP7687682B2 (ja) | 2019-04-08 | 2020-04-08 | 筋疾患治療用医薬組成物 |
| JP2025081949A Pending JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025081949A Pending JP2025118886A (ja) | 2019-04-08 | 2025-05-15 | 筋疾患治療用医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220175817A1 (https=) |
| EP (1) | EP3954395A4 (https=) |
| JP (2) | JP7687682B2 (https=) |
| CN (1) | CN113677374A (https=) |
| WO (1) | WO2020209285A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| CN117120456A (zh) * | 2020-12-11 | 2023-11-24 | 卫材R&D管理有限公司 | 聚-吗啉代寡核苷酸缺口体 |
| EP4349986A4 (en) * | 2021-05-25 | 2025-11-19 | Univ Nat Corp Tokyo Medical & Dental | HETERONUCLEIC ACID WITH A CONTENT OF ?????? OR ???? |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JPWO2023022229A1 (https=) * | 2021-08-19 | 2023-02-23 | ||
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| WO2023027125A1 (ja) | 2021-08-24 | 2023-03-02 | ペプチドリーム株式会社 | ヒトトランスフェリンレセプター結合抗体－ペプチドコンジュゲート |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023390632A1 (en) | 2022-12-09 | 2025-07-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| JP2024089860A (ja) * | 2022-12-22 | 2024-07-04 | 学校法人東京薬科大学 | Ｚｉｃ５発現を調節するための核酸複合体 |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4689110A1 (en) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026080897A1 (en) | 2024-10-11 | 2026-04-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of chronic pain |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060014289A1 (en) * | 2004-04-20 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| CA2666191C (en) | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| BR122020021379B1 (pt) * | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| EP2421971B1 (en) * | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| JP6112569B2 (ja) | 2011-12-16 | 2017-04-12 | 国立大学法人 東京医科歯科大学 | キメラ２重鎖核酸 |
| WO2014132671A1 (en) * | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| US20140315977A1 (en) * | 2013-03-14 | 2014-10-23 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| EP3004347B1 (en) | 2013-05-30 | 2018-09-26 | National University Corporation Tokyo Medical and Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| AU2014282666A1 (en) * | 2013-06-16 | 2016-01-07 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| JP6707028B2 (ja) * | 2013-12-09 | 2020-06-10 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 心筋細胞新生におけるｈｉｐｐｏ及びジストロフィン複合体シグナル伝達 |
| JP2018528783A (ja) * | 2015-09-25 | 2018-10-04 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | コンジュゲートアンチセンス化合物及びその使用 |
| EP3858993A1 (en) * | 2015-10-09 | 2021-08-04 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| JPWO2017068790A1 (ja) * | 2015-10-23 | 2018-08-09 | レナセラピューティクス株式会社 | 核酸複合体 |
| EP3517610A4 (en) * | 2016-09-23 | 2020-05-27 | National University Corporation Tokyo Medical and Dental University | THROUGH HETERODUPLEX NUCLEIC ACID THROUGH BLOOD BRAIN CABINET |
| US11260134B2 (en) * | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| EP3571300A1 (en) | 2017-01-19 | 2019-11-27 | ProQR Therapeutics II B.V. | Oligonucleotide complexes for use in rna editing |
| GB201711809D0 (en) * | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| WO2019067981A1 (en) * | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
| JP2019073832A (ja) | 2017-10-18 | 2019-05-16 | 合同会社型壱 | 帽子の製造方法、及びこれに用いる型 |
-
2020
- 2020-04-08 CN CN202080025994.6A patent/CN113677374A/zh active Pending
- 2020-04-08 US US17/602,035 patent/US20220175817A1/en active Pending
- 2020-04-08 JP JP2021513667A patent/JP7687682B2/ja active Active
- 2020-04-08 EP EP20788494.1A patent/EP3954395A4/en active Pending
- 2020-04-08 WO PCT/JP2020/015818 patent/WO2020209285A1/ja not_active Ceased
-
2025
- 2025-05-15 JP JP2025081949A patent/JP2025118886A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020209285A5 (https=) | ||
| JP2023123491A5 (https=) | ||
| CN114681621B (zh) | 肽寡核苷酸缀合物 | |
| JP5209204B2 (ja) | ポリマーオリゴヌクレオチドプロドラッグ | |
| JPWO2023026994A5 (https=) | ||
| JP2010533171A5 (https=) | ||
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| US20200385735A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP2018530560A5 (https=) | ||
| JP2024511955A5 (https=) | ||
| JP2021500016A5 (https=) | ||
| JP2021532784A (ja) | アンチセンス送達のための三量体ペプチド | |
| JPWO2023022229A5 (https=) | ||
| CN114615998A (zh) | 缀合物及其用途 | |
| JP2025508337A5 (https=) | ||
| JP2024511954A5 (https=) | ||
| US20040072743A1 (en) | Pharmaceutical composition of modified pna molecules | |
| WO2015172889A1 (de) | Peptid-nukleinsäuren-monomere und -oligomere | |
| JP2013537404A5 (https=) | ||
| JPWO2021187392A5 (https=) | ||
| AU2021226089A1 (en) | Antisense nucleic acid inducing skipping of exon 51 | |
| IL317141A (en) | Oleic acid-conjugated oligonucleotides and uses thereof | |
| JP2001524942A (ja) | アンチセンス・オリゴヌクレオチド薬物 | |
| Tamamura et al. | Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation | |
| JP2004538272A5 (https=) |